Abstract: Disclosed is a method of controlling postprandial blood glucose levels in a subject. The method includes orally administering to a subject an orally administrable oligoethylene glycol conjugate of insulin or an orally administrable insulin fusion protein. Oral administration is done during a time period from about 5 to 25 minutes prior to a meal.

Abstract: The present invention provides for a specific and sensitive bio-analytical method for detection of insulin or insulin analogues in plasma, serum or any other biological fluid, wherein the insulin or insulin analogues are labelled with a stable isotopic nitrogen for detection by the use of solid phase extraction and liquid chromatography with tandem mass spectrometric detection.

Abstract: The invention relates to improvised pharmaceutical compositions permitting ingestion via oral delivery of proteins/peptides or their conjugates, and/or cation-insulin conjugate complexes demonstrating desirable pharmacokinetic profiles and potency in efficacy models of diabetes in dogs and humans. A preferred formulation comprises 0.01%-20% w/w of insulin, insulin compound conjugates and/or cation insulin conjugates, 10%-60% w/w of one or more fatty acid components selected from saturated or unsaturated C4-C12 fatty acids and/or salts of such fatty acids and additionally contains optimal amounts of other pharmaceutically suitable polymer excipients which permit improved solubility, dissolution rate and effective bioavailability of poorly water soluble compositions and consistent in-vivo release profiles upon scalability during manufacture. A further aspect of the invention features the process of preparing the aforesaid formulations.

Abstract: The present invention discloses novel process for the preparation of mixture of polypeptides comprising L-Glutamaic acid, L-Alanine, L-Tyrosine, and L-Lysine. by employing circular dichroism as a guidance tool.

Abstract: The invention claims a process for making an insulin-oligomer conjugate IN-105. IN-105 precursor having formula G-A-V-R-[B-Chain]-R-D-A-D-D-R-[A-Chain] is cloned and expressed in Pichia. The biosynthetic precursor is then conjugated with an activated oligomer. The IN-105 precursor-oligomer conjugate is then treated with protease and purified to afford active insulin-oligomer conjugate of formula insulin-OC—CH2—CH2—(OCH2CH2)3—OCH3.

Abstract: The present invention discloses a new strain of Streptomyces sp. BICC 7522, its variants or mutants and use of the strain for the production of macrolides, process of production and purification of macrolides.

Abstract: The present invention discloses a process for making an insulin-oligomer conjugate as a one-pot reaction by conjugation of insulin-ester with an activated oligomer wherein simultaneous deblocking and conjugation is carried out.

Abstract: The invention claims a process for making an insulin-oligomer conjugate IN-105. IN-105 precursor having formula G-A-V-R-[B-Chain]-R-D-A-D-D-R-[A-Chain] is cloned and expressed in Pichia. The biosynthetic precursor is then conjugated with an activated oligomer. The IN-105 precursor-oligomer conjugate is then treated with protease and purified to afford active insulin-oligomer conjugate of formula insulin-OC—CH2—CH2—(OCH2CH2)3—OCH3.

Abstract: The invention relates to improvised pharmaceutical compositions permitting ingestion via oral delivery of proteins/peptides or their conjugates, and/or cation-insulin conjugate complexes demonstrating desirable pharmacokinetic profiles and potency in efficacy models of diabetes in dogs and humans. A preferred formulation comprises 0.01%-20% w/w of insulin, insulin compound conjugates and/or cation insulin conjugates, 10%-60% w/w of one or more fatty acid components selected from saturated or unsaturated C4-C12 fatty acids and/or salts of such fatty acids and additionally contains optimal amounts of other pharmaceutically suitable polymer excipients which permit improved solubility, dissolution rate and effective bioavailability of poorly water soluble compositions and consistent in-vivo release profiles upon scalability during manufacture. A further aspect of the invention features the process of preparing the aforesaid formulations.

Abstract: The present invention discloses a new strain of Streptomyces sp. BICC 7522, its variants or mutants and use of the strain for the production of macrolides, process of production and purification of macrolides.

Abstract: The present invention discloses a new strain of Streptomyces sp. BICC 7522, its variants or mutants and use of the strain for the production of macrolides, process of production and purification of microlides.

Abstract: The present invention discloses a new strain of Streptomyces sp. BICC 7522, its variants or mutants and use of the strain for the production of macrolides, process of production and purification of microlides.

Abstract: The present invention discloses a process for making an insulin-oligomer conjugate as a one-pot reaction by conjugation of insulin-ester with an activated oligomer wherein simultaneous deblocking and conjugation is carried out.

Abstract: Process for the recovery of a macrolide in substantially pure form comprising: a) treatment of an impure or crude macrolide with water immiscible solvent, b) optional concentration of the mixture, c) treatment with ammonia gas to phase out impurities, d) separation of impurities, d) optional concentration of the phase containing the macrolide, f) loading on silica gel chromatography, optionally reversed phase or pretreated with silver, and elution of the macrolide, g) affording the macrolide in substantially pure form, h) optional repetition of step f) and g) to afford the macrolide in substantially pure form. The macrolide is preferably tacrolimus, immunomycin or sirolimus.

Abstract: Methods for the manufacture of Mycophenolate are disclosed. Mycophenblate mofetil is biochemically synthesized using Mycophenolic Acid and 2-morpholino ethanol with the help of an enzyme. Mycophenolate mofetil is also chemically synthesized non-catalytically by refluxing mycophenolic acid with 2-morpholino ethanol in the absence of a third solvent or a catalyst.